home / stock / lumo / lumo news

LUMO News and Press, Lumos Pharma Inc. From 08/09/23

Stock Information
Company Name: Lumos Pharma Inc.
Stock Symbol: LUMO
Market: NASDAQ
Website: lumos-pharma.com
Menu
LUMO LUMO Quote LUMO Short LUMO News LUMO Articles LUMO Message Board
Get LUMO Alerts

News, Short Squeeze, Breakout and More Instantly...
LUMO - Lumos Pharma GAAP EPS of -$1.09 misses by $0.02, revenue of $0.53M beats by $0.33M

2023-08-09 16:37:39 ET Lumos Pharma press release ( NASDAQ: LUMO ): Q2 GAAP EPS of -$1.09 misses by $0.02 . Revenue of $0.53M (+32.5% Y/Y) beats by $0.33M . Ended the quarter on June 30, 2023 with cash, cash equivalents and short-term investments totaling ...
LUMO - Lumos Pharma Reports Second Quarter 2023 Financial Results, Provides Clinical Update

Confirms Timing for Primary Outcome Data Readout for two Phase 2 OraGrowtH Trials in Q4 2023 Late Breaking Abstract Accepted for Oral Presentation at ESPE 2023 Encouraging Interim Data from OraGrowtH Trials Presented at ENDO 2023, Highlighted in KOL Webinar Conference Call...

LUMO - Lumos Pharma to Report Second Quarter 2023 Financial Results and Host Conference Call on August 9, 2023

AUSTIN, Texas, July 26, 2023 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for Pediatric Growth Hormone Deficiency (PGHD) through Phase 2 clinical trials, announced it will report its second quarter 2023 financial res...

LUMO - Lumos Pharma to Participate in the Oppenheimer 2023 Montauk Life Sciences Summit

AUSTIN, Texas, July 12, 2023 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for Pediatric Growth Hormone Deficiency (PGHD) through Phase 2 clinical trials, announced that the Company’s President & Chief Scie...
LUMO - Lumos Pharma Announces Departure of Chief Medical Officer

AUSTIN, Texas, June 28, 2023 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for idiopathic Pediatric Growth Hormone Deficiency (iPGHD) through Phase 2 clinical trials, announced today that Chief Medical Officer (CMO) D...

LUMO - Lumos to Highlight New LUM-201 Data and Analysis Presented at ENDO 2023 in Virtual KOL Webinar

Webinar to Review Data Demonstrating Potential Drug Effect and Durable Response Webinar to be held Today June 21, 2023 at 11:00 AM Eastern Time AUSTIN, Texas, June 21, 2023 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral ...

LUMO - Lumos Pharma to Participate in the Upcoming 2023 BIO International Convention and the Jefferies Healthcare Conference

AUSTIN, Texas, May 31, 2023 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for Pediatric Growth Hormone Deficiency (PGHD) through Phase 2 clinical trials, announced that the Company will participate in the 2023 BIO Int...
LUMO - Lumos Pharma Announces Abstracts Accepted for Oral Presentation at 2023 ENDO Meeting with Virtual KOL Event to be Held on June 21st

AUSTIN, Texas, May 25, 2023 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for idiopathic Pediatric Growth Hormone Deficiency (iPGHD) through Phase 2 clinical trials, announced today that interim data from its OraGrowt...

LUMO - Lumos Pharma to Participate in World Orphan Drug Congress USA

AUSTIN, Texas, May 22, 2023 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for idiopathic Pediatric Growth Hormone Deficiency (iPGHD) through Phase 2 clinical trials, announced today that management will participate in...

LUMO - Encouraging Data from Lumos Pharma OraGrowtH Trials Presented at Annual Pediatric Endocrine Society Meeting (PES)

Oral and Poster Presentations on OraGrowtH Trials at PES 2023 Further Support Potential for LUM-201 as First Oral Treatment for Moderate Idiopathic PGHD OraGrowtH212 Interim Data Demonstrate LUM-201 Amplifies Natural Pulsatile GH-Secretion and that IGF-1 SDS and Serum Concentrations Rem...
Previous 10 Next 10